Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. (Q45929654)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 September 2013

Language	Label	Description	Also known as
English	Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.	scientific article published on 14 September 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

1 reference

based on heuristic

inferred from title

author name string

Jun Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Dali Li

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Baocheng Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Yun Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

language of work or name

0 references

publication date

14 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

141

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

213-224

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Current and emerging biomarkers in breast cancer: prognosis and prediction

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

HuR regulates beta-tubulin isotype expression in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

MiR-200c and HuR in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

MicroRNA-125a represses cell growth by targeting HuR in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Identifiers

10.1007/S10549-013-2679-7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45929654&oldid=2207465109"